N-(4-Phenyl-thiazol-2-yl)-benzenesulfonamide | 15850-37-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-Phenyl-thiazol-2-yl)-benzenesulfonamide
• 英文别名: N-(4-phenyl-1,3-thiazol-2-yl)benzenesulfonamide
• CAS: 15850-37-0
• 化学式: C₁₅H₁₂N₂O₂S₂
• 分子量: 316.404
• InChiKey: AWNIIYIQMZGLMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  95.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(4-Phenyl-thiazol-2-yl)-benzenesulfonamide 、 N,N-二甲基甲酰胺 在 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 以25 %的产率得到2-[(1E)-1-aza-2-(dimethylamino)vinyl]-4-phenyl-1,3-thiazole-5-carboxaldehyde
  参考文献：
  名称：

  N-保护2-氨基-4-苯基噻唑化合物的甲酰化反应

  摘要：

  研究了4-苯基-NN'-苯甲酰基和4-苯基-N-取代（N-磺酰基和N-苯基）-2-氨基噻唑分子与POCl 3 /DMF的Vilsmeier Haack甲酰化反应。晶体(6) ((E) -N' - (5-甲酰基-4-苯基噻唑-2-基)-N ,N-二甲基甲酰亚胺酰胺)和晶体(14) ( N-苯基-N- (4-苯基噻唑) -2-基)甲酰胺)分子是在NN'苯甲酰基、N-磺酰基保护基4-苯基噻唑分子的甲酰化反应中得到的。在N-苯基取代的噻唑类化合物，在胺基上加成醛基取代噻唑环，形成N-苯基-N- (4-苯基噻唑-2-基)甲酰胺分子。所有化合物均已合成并通过 FT-IR、1 H-NMR、13 C-NMR 技术和 X 射线结构分析进行了表征。这些分子展示了 O,S-syn 构象。

  DOI：

  10.1016/j.molstruc.2023.135840

文献信息

• [EN] KYNURENINE 3-MONOOXYGENASE (KMO) INHIBITORS, AND USES AND COMPOSITIONS THEREOF<br/>[FR] INHIBITEURS DE LA KYNURÉNINE 3-MONOOXYGÉNASE (KMO), ET UTILISATIONS ET COMPOSITIONS ASSOCIÉES
  申请人：UNIV LEICESTER

  公开号：WO2019102186A1

  公开（公告）日：2019-05-31

  There is provided compounds of formula (I) or pharmaceutically-acceptable salts thereof, wherein: L, X, R1, R2 and n have meanings provided in the description, which compounds are useful in the treatment of neurodegenerative and neuroinflammatory diseases.

  提供了具有以下结构式（I）或其药用盐的化合物，其中：L、X、R1、R2和n的含义如描述中所提供的，这些化合物在治疗神经退行性和神经炎症性疾病方面是有用的。
• Treatment of aneurysms
  申请人：Georgia State University Research Foundation, Inc.

  公开号：US11376248B2

  公开（公告）日：2022-07-05

  The present invention provides methods for detecting and/or treating a subject having an aneurysm or at risk for developing an aneurysm. It has been discovered that a key metabolite of the kynurenine (Kyn) pathway, a major route for the metabolism of essential amino acid tryptophan (Trp) into nicotinamide adenine dinucleotide (NAD+), plays a critical role in the formation of aneurysms, for example abdominal aortic aneurysms. In particular, it has been discovered that 3-Hydroxyanthranilic acid (3-HAA), a product of kynureninase (KYNU), plays a causative role in the formation of aneurysms by, for example exerting pro-inflammatory effects on vascular smooth muscle cells. It has further been discovered that elevated levels of 3-HAA are indicative of the presence and/or progression of an aneurysm, and 3-HAA levels correlate with the size (aortic diameter) of the aneurysm.

  本发明提供了检测和/或治疗患有动脉瘤或有罹患动脉瘤风险的受试者的方法。现已发现，犬尿氨酸（Kyn）途径的一种关键代谢物--将必需氨基酸色氨酸（Trp）代谢为烟酰胺腺嘌呤二核苷酸（NAD+）的主要途径--在动脉瘤（例如腹主动脉瘤）的形成中起着关键作用。特别是，研究发现，3-羟基氨基苯甲酸（3-HAA）是犬尿苷酶（KYNU）的产物，通过对血管平滑肌细胞产生促炎作用等方式，在动脉瘤的形成过程中起着致病作用。研究进一步发现，3-HAA 水平的升高表明动脉瘤的存在和/或发展，3-HAA 水平与动脉瘤的大小（主动脉直径）相关。
• KYNURENINE 3-MONOOXYGENASE (KMO) INHIBITORS, AND USES AND COMPOSITIONS THEREOF
  申请人：University of Leicester

  公开号：EP3713935A1

  公开（公告）日：2020-09-30
• TREATMENT OF ANEURYSMS
  申请人：Georgia State University Research Foundation, Inc.

  公开号：US20200138810A1

  公开（公告）日：2020-05-07

  The present invention provides methods for detecting and/or treating a subject having an aneurysm or at risk for developing an aneurysm. It has been discovered that a key metabolite of the kynurenine (Kyn) pathway, a major route for the metabolism of essential amino acid tryptophan (Trp) into nicotinamide adenine dinucleotide (NAD+), plays a critical role in the formation of aneurysms, for example abdominal aortic aneurysms. In particular, it has been discovered that 3-Hydroxyanthranilic acid (3-HAA), a product of kynureninase (KYNU), plays a causative role in the formation of aneurysms by, for example exerting pro-inflammatory effects on vascular smooth muscle cells. It has further been discovered that elevated levels of 3-HAA are indicative of the presence and/or progression of an aneurysm, and 3-HAA levels correlate with the size (aortic diameter) of the aneurysm.
• [EN] A CELLULAR DRUG SCREENING METHOD USING FACS AND LC-MS.<br/>[FR] PROCÉDÉ CELLULAIRE DE CRIBLAGE DE MÉDICAMENTS À L'AIDE DU TRI DE CELLULES ACTIVÉES PAR FLUORESCENCE ET DU COUPLAGE CHROMATOGRAPHIE LIQUIDE-SPECTROMÉTRIE DE MASSE
  申请人：UNIV EDINBURGH

  公开号：WO2015082900A1

  公开（公告）日：2015-06-11

  Described herein are new methods for the rapid screening of compounds for a multiplicity of parameters in a single stage. More particularly, there is provided a novel screening method for the assessment of protein binding, cellular permeability and cytotoxicity of compounds in a single stage.